HER2 positive breast carcinoma

This early-phase study tested a personalized vaccine made from a patient's own immune cells, designed to target a protein called HER-2 found on some aggressive breast cancers. The goal was to see if the vaccine was safe and could train the immune system to prevent the cancer from…

Researchers are comparing two first-line treatment strategies for women with advanced HER2-positive breast cancer: pertuzumab plus trastuzumab and docetaxel, versus trastuzumab and docetaxel alone. The study uses real-world electronic health records from about 2,250 patients trea…

This trial tests an experimental drug called zanidatamab, which targets HER2, a protein that fuels certain breast and stomach cancers. Researchers give zanidatamab alongside chemotherapy, and sometimes with the immunotherapy tislelizumab, to people with advanced HER2-positive bre…

This phase II trial is testing whether a combination of palbociclib (a targeted pill), hormone therapy, and HER2-targeted drugs can shrink early-stage breast tumors as effectively as standard chemotherapy before surgery. Postmenopausal women with hormone receptor-positive, HER2-p…

This study tested a combination of three drugs (atezolizumab, pertuzumab, and high-dose trastuzumab) in 19 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the treatment could shrink or control brain tumors. While the approach aims to m…

This study looks at how well trastuzumab deruxtecan (T-DXd) works and how safe it is in women with HER2-positive metastatic breast cancer. The drug is given as an intravenous infusion every three weeks to patients who have already tried other anti-HER2 treatments. Researchers wil…

This phase III trial is investigating whether adding lapatinib to the standard combination of paclitaxel and trastuzumab before surgery can improve outcomes for patients with HER2-positive stage II or III breast cancer. The study aims to see if the three-drug regimen leads to a h…

This phase II study tested a combination of two chemotherapy drugs (cyclophosphamide and paclitaxel) plus the targeted drug trastuzumab given after surgery to 20 patients with early-stage HER2-positive breast cancer. The goal was to see if this regimen is safe and can help preven…

This phase II trial is testing whether adding two HER2-targeted drugs (trastuzumab and pertuzumab) to the chemotherapy gemcitabine can help people with metastatic HER2-positive breast cancer who have already received similar treatments. The study aims to see how long the cancer s…

This trial tests an experimental drug called TQB2102 for people with HER2-positive breast cancer that has returned or spread to other parts of the body. TQB2102 is an antibody-drug conjugate—a targeted therapy that binds to HER2 on cancer cells and releases a potent chemotherapy …

This trial investigates whether adding everolimus (RAD001) to trastuzumab (Herceptin) can help people with a specific type of advanced breast cancer that has stopped responding to trastuzumab alone. The study includes people with HER2-positive, PTEN-deficient metastatic breast ca…

This study tested whether two drugs, zanidatamab and evorpacept, are safe and can shrink tumors in people with advanced HER2-expressing cancers. Fifty-two patients with breast or other cancers that had spread or couldn't be removed by surgery took part. The goal was to see how ma…

This phase 2 trial tests a new drug called TVB-2640 (denifanstat) combined with trastuzumab and either chemotherapy (paclitaxel) or hormone therapy in 17 people with HER2+ metastatic breast cancer that no longer responds to trastuzumab. TVB-2640 blocks an enzyme cancer cells need…

This phase II trial tested a combination of two targeted antibodies (pertuzumab and trastuzumab) plus a chemotherapy drug (nab-paclitaxel) in 63 patients with HER2-positive advanced breast cancer. The goal was to see how well the drugs work together to stop tumor growth and impro…

This study tested whether taking oral chemotherapy pills (vinorelbine or capecitabine) along with the targeted drug trastuzumab can help prevent breast cancer from coming back in women with small, HER2-positive tumors that have not spread to lymph nodes. The 182 participants took…

This phase 2 trial tests BB-1701, a drug that targets HER2 on breast cancer cells, in 56 people with advanced breast cancer that is HER2-positive or HER2-low. The study has two parts: first to find the best dose, then to see how well it shrinks tumors. Participants receive the dr…

This early-phase study tested a vaccine made from patients' own immune cells to target HER2-positive breast cancer. 31 participants with stage II or III breast cancer received the vaccine alongside standard chemotherapy before surgery. The goal was to see if the vaccine could boo…

This early-phase trial tested a combination of two drugs—copanlisib and trastuzumab—in 26 women with advanced HER2-positive breast cancer that had worsened after prior treatment. The goal was to find the safest dose and see if the combination could shrink tumors or slow disease p…

This study tested a new drug called taselisib combined with standard anti-HER2 therapies in 68 people with advanced HER2+ breast cancer. The goal was to find the safest dose and see if the combination could shrink tumors or slow the disease. While not a cure, the approach aims to…

This early-phase trial tested an experimental drug called BAT8010 in 23 people with advanced or metastatic solid tumors who had no other standard treatment options. The main goals were to check safety, find the best dose, and see if the drug shows any sign of shrinking tumors. Pa…

This study tested a combination of two drugs, tucatinib and trastuzumab deruxtecan (T-DXd), in 70 people with advanced HER2-positive breast cancer that had spread or couldn't be removed by surgery. The goal was to see how well the drugs shrank tumors and what side effects occurre…

This study tested whether a device that uses focused ultrasound can safely and temporarily open the blood-brain barrier in people with HER2-positive breast cancer that has spread to the brain. Eight participants received the procedure, and researchers checked for side effects and…

This study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…

This early-phase trial tested a new drug, ipatasertib, added to two existing breast cancer medicines (trastuzumab and pertuzumab) in 17 people with advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation). The main goal was to find the safest dose…

This study tested a new drug, trastuzumab deruxtecan (DS-8201a), against standard treatments for people with advanced HER2-positive breast cancer that had already been treated with T-DM1. The trial included 608 participants whose cancer could not be removed by surgery or had spre…

This completed Phase 3 trial tested whether a fixed-dose combination of two targeted drugs (pertuzumab and trastuzumab) given as a simple shot under the skin works as well as the standard IV infusion in 200 Chinese patients with HER2-positive early breast cancer. The study measur…

This study tested whether a drug called T-DM1 causes fewer side effects than the standard treatment of paclitaxel plus trastuzumab in people with stage I HER2-positive breast cancer. About 500 participants were randomly assigned to one of the two treatments. The researchers also …

This study tested a drug called neratinib, alone or with other medicines, in 140 people with HER2-positive breast cancer that spread to the brain. The goal was to see if the drug could shrink or stabilize brain tumors. Results help doctors understand how well this treatment works…

This study looked at how well the drug tucatinib (Tukysa) works in everyday medical practice for people with advanced HER2-positive breast cancer who had already tried at least two other treatments. Researchers tracked 49 adults in Germany and Austria to see how their quality of …

This study tested whether adding the drug pertuzumab to standard chemotherapy and trastuzumab could help prevent breast cancer from returning after surgery. About 4,800 people with HER2-positive breast cancer took part. The results showed that the three-drug combination improved …

This study looked at 178 Chinese patients with HER2-positive advanced breast cancer who received the drug T-DM1 after earlier treatments failed. Researchers tracked side effects and how long the drug kept the cancer from getting worse. The goal was to see how well T-DM1 works in …

This Phase 3 trial tested whether replacing standard taxane chemotherapy (paclitaxel or docetaxel) with eribulin, when combined with pertuzumab and trastuzumab, could control advanced HER2-positive breast cancer just as well while causing less nerve damage. The study enrolled 446…

This early-phase trial tested an experimental drug called FS1502 in 161 people with advanced solid tumors or breast cancer that express HER2. The study had two parts: first, finding a safe dose, and then seeing how well that dose works. The goal was to check safety and early sign…

This phase 3 trial tested whether giving pertuzumab again, along with trastuzumab and chemotherapy, could help people with HER2-positive advanced breast cancer who had already received pertuzumab before. The study enrolled 226 participants and compared retreatment to standard tra…

This study tests two new radioactive imaging agents, 99mTc-ADAPT6 and 99mTc-DARPinG3, to see how well they can detect HER2-positive breast cancer using SPECT scans. Fifteen women with HER2-positive breast cancer will receive injections of each agent a few days apart, followed by …

This study tested a special imaging tracer (99mTc-DARPinG3) to measure HER2 protein levels in breast cancer tumors using SPECT scans. Fifteen women with HER2-positive breast cancer received the tracer before and during chemotherapy plus targeted therapy. The goal was to see if th…

This pilot study tested a new radioactive tracer called 89Zr-DFO*-trastuzumab in 6 people with HER2-positive breast or gastric cancer. The tracer is designed to attach to HER2 proteins on cancer cells and show up on PET scans. Participants received one injection and had up to 4 P…

This study looked at whether people with early or locally advanced HER2-positive breast cancer prefer receiving their medication (a combination of pertuzumab and trastuzumab) at home versus in the hospital. About 346 participants were randomly assigned to receive the drug at home…

This study is testing whether certain markers in the blood can predict how well the drug trastuzumab shrinks tumors in women with early HER2-positive breast cancer. Participants receive trastuzumab before breast-conserving surgery, and researchers compare blood marker levels with…

This study investigates whether tumor DNA found in the blood (called plasma tumor DNA or ptDNA) can predict how well breast cancer responds to chemotherapy given before surgery. Researchers will collect blood samples from 228 people with early-stage, high-risk breast cancer (HER2…

This completed study observed 22 adults with HER2-positive or HER2-low metastatic breast cancer who were taking trastuzumab deruxtecan (Enhertu) as part of routine care. Researchers tracked how many patients stopped treatment early or needed dose changes, and why. The goal is to …

This study follows 600 Chinese women with early-stage HER2-positive breast cancer to see how anti-HER2 treatment affects their quality of life over a year. Participants fill out questionnaires about physical, emotional, and social well-being. The goal is to understand real-world …

This study looked at whether women with early-stage breast cancer benefit from having a breast MRI in addition to standard mammograms before surgery. Researchers tracked 319 women to see if the MRI helped reduce the chance of cancer coming back, lowered the need for repeat surger…

This completed study from Semmelweis University looked at whether the breast cancer drug trastuzumab (Herceptin) causes dry eye or other eye surface problems. 35 adults with HER2-positive breast cancer took the drug as prescribed and visited the clinic every 3 months for eye exam…

This study looked at how two common drugs (ritonavir and itraconazole) change the way the body processes a new experimental drug called SHR-A1811 in people with advanced HER2-positive breast cancer. Seventeen participants received the drug alone and then with each of the other me…

This study looked at how well anti-HER2 drugs work in Egyptian women with HER2-positive breast cancer. Researchers followed 80 patients who received either one drug (trastuzumab) or a combination (trastuzumab plus pertuzumab or lapatinib) as part of their regular care. The goal w…

This study looked at medical records of 86 people with HER2+ metastatic breast cancer to see how well a combination of tucatinib, trastuzumab, and capecitabine worked after they had already received a treatment called T-DXd. The goal was to measure things like time until the next…

This study looked at 200 women with early-stage HER2-positive breast cancer who were taking trastuzumab. The goal was to compare two standard schedules for monitoring heart function: every 3 months versus every 4 months. Researchers wanted to see if less frequent monitoring could…

This study tested whether an automated system can grow cancer cells from patient samples (blood, fluid, or tumor tissue) inside chicken eggs. Researchers aimed to see if at least half of the samples would successfully grow. The goal is to create a better, cheaper way to study can…

This study reviewed medical records of 111 adults with early-stage HER2-positive breast cancer who received the drug neratinib after their initial treatment. The goal was to describe their age, gender, health conditions, and tumor details. This was an observational study, meaning…

This completed study looked at over 1,500 women with early-stage HER2-positive or triple-negative breast cancer who had no signs of cancer in their lymph nodes on ultrasound. All had breast-conserving surgery with lymph node removal. The goal was to see how often cancer actually …